AbCellera Biologics Inc. (NASDAQ:ABCL) Q2 2024 Earnings Conference Call August 6, 2024 5:00 PM ET

Company Participants

Tryn Stimart - Chief Legal and Compliance Officer
Dr. Carl Hansen - Chief Executive Officer
Andrew Booth - Chief Financial Officer

Conference Call Participants

Allison Bratzel - Piper Sandler
Stephen Willey - Stifel
Andrea Tan - Goldman Sachs
Evan Seigerman - BMO
Michael Sonntag - Leerink Partners
Steven Mah - TD Securities
Billal Jahangiri - Truist

Operator

Good afternoon. And welcome to AbCellera’s Q2 2024 Business Update Conference Call. My name is Tamiya, and I will facilitate the audio portion of today’s interactive broadcast. All lines will be muted during the presentation portion of the call with an opportunity for questions-and-answers at the end. [Operator Instructions]

At this time, I would like to turn the call over to Tryn Stimart, AbCellera’s Chief Legal and Compliance Officer. You may proceed.

Tryn Stimart

Thank you. Good morning, good afternoon, and good evening to everyone listening around the world. Thank you for joining us for AbCellera’s 2024 second quarter earnings call. I’m Tryn Stimart, AbCellera’s Chief Legal and Compliance Officer. Joining me on today’s call are Dr. Carl Hansen, and CEO; and Andrew Booth, AbCellera’s Chief Financial Officer.

During this call, we anticipate making projections and forward-looking statements based on our current expectations and pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995.

Our actual results could differ materially due to several factors as set forth in our latest Form 10-K and subsequent Forms 10-Q and 8-K filed with the Securities and Exchange Commission. AbCellera does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. Our presentation today, including our earnings press release issued earlier today, and our SEC filings are available on our Investor Relations website.

The information we provide about our pipeline is for the benefit of the investing community and is not intended to be promotional. As we transition to our prepared remarks, please note that all dollars referred to during the call are in U.S. dollars. After our prepared remarks, we will open the lines for questions-and-answers.

Now, I’ll turn the call over to Carl.

Dr. Carl Hansen

Thanks, Tryn, and thank you, everyone, for joining us today. Through the second quarter, we continue to focus capital allocation on our three priorities; first, building and advancing our internal pipeline; second, completing investments in our platforms and facilities; and third, executing on select strategic partnerships.